CRISPR Therapeutics AG Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (36)

Latest Posts

About This Stock More About This Stock
Bear Market Rally Lifts HealthCare Stocks Off Bottom
Article By: Rod Raynovich
Wednesday, June 22, 2022 5:36 AM EDT
Clearly we are in a biotech bear market with both diagnostics and vaccine revenues stalled. If gene editing stocks cannot offer breakthrough clinical news then stick with large cap biopharma.
In this article: LLY, UNH, XLV, CRSP Also: CCXI, EVH, MRTX, MDGL, VCYT
Read
Crispr: A Fallen Angel In Gene Editing
Article By: MoneyShow.com
Friday, October 15, 2021 11:31 PM EDT
As with most promising biotech companies, investors bid their prices up for CRSP based on its potential for early profits. When the payoff didn't occur on schedule, investors bailed out. Once it becomes profitable, investors will come flocking back.
In this article: CRSP Also: NVAX, VRTX, RHHBY, AMGN, BIIB, GILD
Read
A Comprehensive Guide To Genomic ETFs
Article By: Zacks Investment Research
Sunday, July 11, 2021 1:59 PM EDT
Given the growing applications of gene-editing, it is a rising market which offers endless opportunities. Growing demand for personalized medicine, solid investments and higher R&D activities will soon make genomics the next big thing in the space.
In this article: GNOM, PBE, ARKG, IDNA, NTLA, CRSP Also: BEAM, EDIT
Read
Mid-Cap Biotech Picks: Seasonal Rally Underway
Article By: Rod Raynovich
Saturday, July 3, 2021 6:54 PM EDT
Many Mid-Cap biotech stocks were hit hard after the February peak. We suggest three new mid-cap biotech picks. All three picks can be volatile but very tradable.
In this article: CYRX, CRSP, VCYT Also: ARKG, XBI
Read
Inside Actively Managed Equity ETFs - A Topic Of Increasing Importance
Article By: Herbert Blank
Thursday, February 4, 2021 10:48 AM EDT
Today’s analysis covers sevenal actively managed ETFs. A handful have had tremendous success in performance and asset capture. Most, thus far, have not. Seven ETFs are compared to SPY as a benchmark with distinctive results.
In this article: HUSV, SPY, VTI, ARKW, ARKK, NVTA, FTHI, CRSP, CWS, AIEQ, TTAC
Read

Latest Tweets for $CRSP

No tweets yet!

PARTNER HEADLINES